Natco Pharma Limited has informed the Exchange regarding Cessation of Mr S V V N Appa Rao as Chief Financial Officer of the company w.e.f. February 12, 2026.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma's long-serving Chief Financial Officer, Mr. S.V.V.N. Appa Rao, has ceased in his role due to superannuation (retirement) effective end of business hours on February 12, 2026. The company has appointed Mr. Amit Parekh, currently Executive Vice President – Finance and Accounts, as the new CFO effective February 13, 2026. Mr. Parekh brings over 23 years of experience, including prior stints at Dr. Reddy's Laboratories. Additionally, Mr. Kalakuntla Srinivas Rao has been appointed as Executive Vice President – Pharma Division effective February 12, 2026, bringing 25+ years of pharma industry experience from MSN Labs and Lupin.
The transition is orderly with an internal promotion ensuring continuity in finance leadership, though investors should watch for any strategic shift from the new CFO. The simultaneous appointment of a senior Pharma Division head signals a focus on strengthening core operations.